AMRI announces president for AMRI Europe
pharmafile | May 23, 2012 | Appointment | Business Services, Manufacturing and Production, Research and Development, Sales and Marketing | AMRI, AMRI Europe, CMO
Contract research and manufacturing organisation AMRI has announced the appointment of Ian Shott as president of AMRI Europe.
In this newly created role reporting to Thomas D’Ambra, chairman, president and chief executive, Shott will have responsibility for AMRI’s business operations in Europe, including the company’s site in Wales, UK, and will work closely with AMRI’s European-based business development team.
As the founder of Excelysn, acquired by AMRI in 2010, and with more than 20 years’ experience working with global pharmaceutical, biotechnology, and chemical companies, Shott will lead AMRI’s sales growth in European markets as well as the worldwide effort to continue to expand revenue growth at the Wales manufacturing location.
Shott was the founder and chief executive of Excelsyn – now AMRI UK – acquired in February 2010 to expand the company’s services platform and footprint in Europe. Shott serves as managing director of Shott Consulting Limited, where he provides consulting services to the healthcare and chemical industries, as well as leading industry boards for the British government in science, technology, innovation and business development.
“Mr. Shott brings an intimate knowledge of the AMRI UK site including its capabilities and leadership team, which will enable him to quickly embark on customer and business growth initiatives,” D’Ambra said. “His extensive experience and skills strengthen our position in the European marketplace.
Shott’s earlier career included executive board posts at RhodiaChirex in France, Chirex in the US, Lonza in Switzerland, and AstraZeneca in the UK. He has been particularly involved in creating and/or transforming businesses by a combination of break out development, culture change, organic growth, internal re-engineering and external merger, acquisition and divestment.
Related Content
Top Ten most popular articles on Pharmafile.com this week
This week’s pharmaceutical headlines were dominated by legal spats as the state of New York …
Contact manufacturing ‘is changing the industry’, report finds
The global market for pharma and biopharma contract manufacturing is expected to reach more than …
AMRI buys two Aptuit facilities
Contract research and manufacturing firm AMRI has acquired two businesses from pharmaceutical services company Aptuit …
